Arbutus Biopharma Corp Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Arbutus Biopharma Corp (ABUS) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$49.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-12
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was -$49.00K.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$97.00K.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $58.00K, a 73.39% decline year-over-year.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was -$21.00K, a 133.33% decline year-over-year.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$2.15M.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was -$164.00K, a 1271.43% decline from fiscal 2020.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for fiscal 2020 was $14.00K.
- Arbutus Biopharma Corp debt securities, available-for-sale, unrealized gain (loss) for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.00K 10-Q · filed 2026-08-12 | -$146.00K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | -$97.00K 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-13 | $37.00K derived: sum of 2 quarters · filed 2026-08-12 | $6.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$21.00K 10-Q · filed 2026-08-12 | -$52.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | -$31.00K 10-Q · filed 2026-05-13 | |||
| 2024-09-30 | $218.00K 10-Q · filed 2025-11-13 | $281.00K derived: sum of 2 quarters · filed 2025-11-13 | $331.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $63.00K 10-Q · filed 2025-08-06 | $113.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $50.00K 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $584.00K 10-Q · filed 2024-11-06 | $750.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.60M 10-Q · filed 2024-11-06 | $2.12M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $166.00K 10-Q · filed 2024-08-08 | $1.02M 10-Q · filed 2024-08-08 | $1.54M derived: sum of 3 quarters · filed 2024-08-08 | $629.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $854.00K 10-Q · filed 2024-05-02 | $1.37M derived: sum of 2 quarters · filed 2024-05-02 | $463.00K derived: sum of 3 quarters · filed 2024-05-02 | -$228.00K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $516.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$391.00K derived: sum of 2 quarters · filed 2023-11-07 | -$1.08M derived: sum of 3 quarters · filed 2023-11-07 | -$2.15M 10-K · filed 2023-03-02 |
| 2022-09-30 | -$907.00K 10-Q · filed 2023-11-07 | -$1.60M derived: sum of 2 quarters · filed 2023-11-07 | -$2.67M 10-Q · filed 2023-11-07 | -$2.82M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$691.00K 10-Q · filed 2023-08-03 | -$1.76M 10-Q · filed 2023-08-03 | -$1.91M derived: sum of 3 quarters · filed 2023-08-03 | -$1.94M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$1.07M 10-Q · filed 2023-05-04 | -$1.22M derived: sum of 2 quarters · filed 2023-05-04 | -$1.25M derived: sum of 3 quarters · filed 2023-05-04 | -$1.28M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$148.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$179.00K derived: sum of 2 quarters · filed 2023-03-02 | -$210.00K derived: sum of 3 quarters · filed 2023-03-02 | -$164.00K 10-K · filed 2023-03-02 |
| 2021-09-30 | -$31.00K 10-Q · filed 2022-11-09 | -$62.00K derived: sum of 2 quarters · filed 2022-11-09 | -$16.00K 10-Q · filed 2022-11-09 | -$103.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$31.00K 10-Q · filed 2022-08-04 | -$28.00K 10-Q · filed 2022-08-04 | -$72.00K derived: sum of 3 quarters · filed 2022-08-04 | -$144.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-05 | -$41.00K derived: sum of 2 quarters · filed 2022-05-05 | -$113.00K derived: sum of 3 quarters · filed 2022-05-05 | $9.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$116.00K derived: sum of 2 quarters · filed 2022-03-03 | $6.00K derived: sum of 3 quarters · filed 2022-03-03 | $14.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | -$72.00K 10-Q · filed 2021-11-04 | $50.00K derived: sum of 2 quarters · filed 2021-11-04 | $58.00K 10-Q · filed 2021-11-04 | $301.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $122.00K 10-Q · filed 2021-08-05 | $130.00K 10-Q · filed 2021-08-05 | $373.00K derived: sum of 3 quarters · filed 2021-08-05 | $373.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $251.00K 10-Q · filed 2021-05-05 | $251.00K derived: sum of 2 quarters · filed 2021-05-05 | $251.00K derived: sum of 3 quarters · filed 2021-05-05 | $251.00K derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $0.00 derived: sum of 3 quarters · filed 2021-03-04 | $0.00 10-K · filed 2021-03-04 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-07 | $0.00 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |